Physician profile
James S Johnson
NPI 1851357578
$13,647.50
in general payments reported to CMS, 2019-2025
55 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,795 · 2021: $2,237 · 2022: $2,003 · 2023: $1,820 · 2024: $2,237 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,113.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.31 | 2021-2025 | |
| Novo Nordisk INC | $1,559.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,292.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $977.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $950.87 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $929.64 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $724.54 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.13 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $513.68 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $414.77 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $380.33 | 2022-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $371.11 | 2019-2023 | |
| Corcept Therapeutics | $368.38 | 2023-2024 | Korlym |
| Otsuka America Pharmaceutical, INC. | $214.55 | 2020-2025 | Rexulti |
| Allergan, INC. | $203.16 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.